Molecular pathways and therapeutic targets in lung cancer
View/ Open
Author
Shtivelman, Emma
Hensing, Thomas
Simon, George R.
Dennis, Phillip A.
Otterson, Gregory A.
Salgia, Ravi
Published Version
https://doi.org/10.18632/oncotarget.1891Metadata
Show full item recordCitation
Shtivelman, Emma, Thomas Hensing, George R. Simon, Phillip A. Dennis, Gregory A. Otterson, Raphael Bueno, and Ravi Salgia. 2014. “Molecular pathways and therapeutic targets in lung cancer.” Oncotarget 5 (6): 1392-1433.Abstract
Lung cancer is still the leading cause of cancer death worldwide. Both histologically and molecularly lung cancer is heterogeneous. This review summarizes the current knowledge of the pathways involved in the various types of lung cancer with an emphasis on the clinical implications of the increasing number of actionable molecular targets. It describes the major pathways and molecular alterations implicated in the development and progression of non-small cell lung cancer (adenocarcinoma and squamous cancer), and of small cell carcinoma, emphasizing the molecular alterations comprising the specific blueprints in each group. The approved and investigational targeted therapies as well as the immune therapies, and clinical trials exploring the variety of targeted approaches to treatment of lung cancer are the main focus of this review.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039220/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:12406787
Collections
- HMS Scholarly Articles [17917]
Contact administrator regarding this item (to report mistakes or request changes)